Arena Pharmaceuticals (ARNA) Investors Show No Fear Into PDUFA
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Investors in Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) are showing no fear into the June 27, 2012 PDUFA date for obesity drug Lorcaserin. Shares hit new 52-week high of $7.23 earlier in the session, before backing down a bit.
On May 10, 2012, an FDA panel voted 18 to 4 that the benefits of lorcaserin outweigh the potential risks. However, even with the panel backing and expected approval, some believe a PDUFA date extension is possible.
Analysts at Jefferies see a delay of 3-6 months, although they said it will have no material impact on valuation and they expect approval and a lorcaserin launch in early 2013.
While a PDUFA delay is an obvious concerns, the action in the stock suggests no PDUFA delay and full steam ahead. Maybe someone knows something.
Shares of ARNA last traded at $7.14, up 7.8 percent.
On May 10, 2012, an FDA panel voted 18 to 4 that the benefits of lorcaserin outweigh the potential risks. However, even with the panel backing and expected approval, some believe a PDUFA date extension is possible.
Analysts at Jefferies see a delay of 3-6 months, although they said it will have no material impact on valuation and they expect approval and a lorcaserin launch in early 2013.
While a PDUFA delay is an obvious concerns, the action in the stock suggests no PDUFA delay and full steam ahead. Maybe someone knows something.
Shares of ARNA last traded at $7.14, up 7.8 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Hunterbrook bullish on Modine Manufacturing (MOD)
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
